Medical device company Globus Medical (NYSE: GMED) missed Wall Street’s revenue expectations in Q3 2026, with sales flat year on year at $763.7 million. The company’s full-year revenue guidance of $3.09 billion at the midpoint came in 3.4% below analysts’ estimates. Its non-GAAP profit of $1.23 per share was 2.8% above analysts’ consensus estimates.

Is now the time to buy GMED? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

Globus Medical’s third quarter was marked by flat sales and a negative market reaction, as management cited delayed product launches in the U.S. Spine business and underperformance at Nevro as key factors. CEO Keith Pfeil acknowledged, “I think there are things that we could have done better to achieve the growth that we thought we were going to get,” referencing the impact of timing setbacks and lower contributions from competitive recruiting. Margins improved due to cost controls and synergy execution, but revenue growth failed to materialize as anticipated.

Looking ahead, management’s lowered full-year outlook is shaped by cautious expectations for Nevro’s recovery and limited near-term impact from recent product launches. Pfeil emphasized anticipated contributions from new products, like SCRIPT and XLIF Prone, in 2027, stating, “We are excited about where spine is positioned... those products are meaningfully going to drive revenue in 2027.” CFO Kyle Kline added that continued investment in R&D and a flexible capital acquisition model are expected to pay dividends longer term, though near-term growth remains pressured.

Key insights from management’s remarks

Management attributed the quarter’s results to delays in new product launches, slower Nevro recovery, and a shift toward more flexible capital sales models.

• Delayed U.S. Spine launches: New products like SCRIPT and XLIF Prone were introduced later than planned, limiting their revenue impact in the quarter. Pfeil commented that these delays, combined with lingering production issues, held back growth but are expected to drive results in the coming year as launches scale up.
• Nevro integration and recovery: Nevro, acquired to expand Globus’s pain portfolio, experienced a 26% sales decline as earlier trial volume weakness persisted. Management completed rehiring efforts and is focused on improving sales force execution, but significant revenue recovery is now expected in 2027, aided by the upcoming HFX Elite product.
• Enabling Technologies momentum: The enabling technologies segment, including robotics and navigation, grew 24% year-over-year. Increased sales and deployments of EGPS and EHUB units (up 73% vs. prior year) reflected success in offering more flexible leasing and rental models, laying groundwork for future implant pull-through.
• Trauma business steady growth: The trauma segment delivered 19% growth, with management noting a shift in market perception from Globus being a “spine company dabbling in trauma” to a committed trauma solutions provider. Growth strategy centers on deeper penetration into Level 1 and 2 trauma centers and new product uptake.
• Small tuck-in acquisitions: Two small deals—Higgs Boson (digital surgical intelligence) and Synaptive (cranial neurosurgery technologies)—were completed. While not expected to contribute meaningful revenue in the near term, these acquisitions expand Globus’s technology base and open new growth markets for the future.

Drivers of future performance

Globus Medical’s outlook depends on new product adoption, Nevro stabilization, and sustained margin discipline amid continued investment in R&D.

• New product contribution in 2027: Management expects products like SCRIPT, XLIF Prone, and eIQ to become meaningful growth drivers as they ramp next year, with early surgeon feedback described as highly positive and anticipation building in the market.
• Nevro turnaround and innovation: The company is focused on stabilizing Nevro, with the HFX Elite product launch and improved sales force productivity expected to revive growth. Management says recovery depends on both execution and competitive recruiting gains.
• Margin and investment trade-off: Continued gross margin improvements are anticipated from manufacturing synergies and sales mix, but these will be partly offset by stepped-up R&D spending as the company invests in both organic product development and integration of recent acquisitions.

Catalysts in upcoming quarters

In the coming quarters, the StockStory team will closely watch (1) the pace and scale-up of SCRIPT and XLIF Prone adoption among surgeons, (2) progress in Nevro’s sales force productivity and the commercial launch of HFX Elite, and (3) further margin expansion from manufacturing synergies and cost controls. The impact of recent acquisitions on portfolio breadth and early traction in cranial neurosurgery will also be important markers.

Globus Medical currently trades at $77.78, down from $81.52 just before the earnings. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it’s free).

Our favorite stocks right now

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.